NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,509.84 mln
Float115 mln
Earnings Date05/13/2026
EPS
1.68
Moderate
P / E
17.23
Moderately valued
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.79
Caution advised
1-Year Forecast
34.14
Attractive
Relative Strength
92
/ 100
Top performer
Business Description
Catalyst Pharmaceuticals is a Florida-based company that develops and sells treatments for patients with rare and serious medical conditions. Its current portfolio includes three approved medicines targeting nerve and muscle disorders, including Lambert-Eaton myasthenic syndrome, certain types of epilepsy, and Duchenne muscular dystrophy. The company also works with outside partners to expand its reach through licensing and development agreements.